Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeike Biewenga

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Biometrical Journal. Biometrische Zeitschrift|September 28, 2018
Bayesian knowledge integration for an in vitro-in vivo correlation modelElvira M Erhardt, Moreno Ursino, Jeike Biewenga, et al.
Clinical Pharmacology in Drug Development|June 23, 2015
Absence of QTc Prolongation with Domperidone: A Randomized, Double-Blind, Placebo- and Positive-Controlled Thorough QT/QTc Study in Healthy VolunteersJeike Biewenga, Chi Keung, Bhavna Solanki, et al.
Journal of Clinical Pharmacology|May 15, 2021
Population Pharmacokinetic Analysis of Bedaquiline-Clarithromycin for Dose Selection Against Pulmonary Nontuberculous Mycobacteria Based on a Phase 1, Randomized, Pharmacokinetic StudyKen Kurosawa, Stefaan Rossenu, Jeike Biewenga, et al.
Advances in Therapy|July 4, 2019
Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy SubjectsJoris Vandenbossche, Wolfgang Jessner, Maarten van den Boer, et al.
Clinical Pharmacology in Drug Development|September 5, 2022
Drug-Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379 (Bersacapavir)Joris Vandenbossche, Jeysen Yogaratnam, Vera Hillewaert, et al.
Advances in Therapy|March 6, 2020
Correction to: Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy SubjectsJoris Vandenbossche, Wolfgang Jessner, Maarten van den Boer, et al.
Journal of Psychopharmacology (Oxford, England)|September 28, 2018
Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participantsMaarten Timmers, Paulien Ravenstijn, Liwen Xi, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|October 4, 2016
IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classesAdam S Darwich, Alison Margolskee, Xavier Pepin, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|November 7, 2016
IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of resultsAlison Margolskee, Adam S Darwich, Xavier Pepin, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Biometrical Journal. Biometrische Zeitschrift|September 28, 2018
Bayesian knowledge integration for an in vitro-in vivo correlation modelElvira M Erhardt, Moreno Ursino, Jeike Biewenga, et al.
Clinical Pharmacology in Drug Development|June 23, 2015
Absence of QTc Prolongation with Domperidone: A Randomized, Double-Blind, Placebo- and Positive-Controlled Thorough QT/QTc Study in Healthy VolunteersJeike Biewenga, Chi Keung, Bhavna Solanki, et al.
Journal of Clinical Pharmacology|May 15, 2021
Population Pharmacokinetic Analysis of Bedaquiline-Clarithromycin for Dose Selection Against Pulmonary Nontuberculous Mycobacteria Based on a Phase 1, Randomized, Pharmacokinetic StudyKen Kurosawa, Stefaan Rossenu, Jeike Biewenga, et al.
Advances in Therapy|July 4, 2019
Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy SubjectsJoris Vandenbossche, Wolfgang Jessner, Maarten van den Boer, et al.
Clinical Pharmacology in Drug Development|September 5, 2022
Drug-Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379 (Bersacapavir)Joris Vandenbossche, Jeysen Yogaratnam, Vera Hillewaert, et al.
Advances in Therapy|March 6, 2020
Correction to: Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy SubjectsJoris Vandenbossche, Wolfgang Jessner, Maarten van den Boer, et al.
Journal of Psychopharmacology (Oxford, England)|September 28, 2018
Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participantsMaarten Timmers, Paulien Ravenstijn, Liwen Xi, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|October 4, 2016
IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classesAdam S Darwich, Alison Margolskee, Xavier Pepin, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|November 7, 2016
IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of resultsAlison Margolskee, Adam S Darwich, Xavier Pepin, et al.
Pageof 1